Last reviewed · How we verify
Superparamagnetic Iron Oxide
At a glance
| Generic name | Superparamagnetic Iron Oxide |
|---|---|
| Also known as | MagTrace, Magtrace |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging (PHASE1)
- Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases (PHASE2)
- Lymph Node Identification Using Magtrace and Magseed Before Chemotherapy
- Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) (PHASE2)
- A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
- Handheld MPI Imaging to Track Stem Cells in Osteoarthritis (EARLY_PHASE1)
- Virtual Histology of the Bladder Wall for Bladder Cancer Staging (EARLY_PHASE1)
- Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Superparamagnetic Iron Oxide CI brief — competitive landscape report
- Superparamagnetic Iron Oxide updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI